Peter Brink’s Post

This #BrainInjuryAwarenessMonth is the perfect time to spotlight advancements in neurology. Our Q-FiberMapper tool is a vital asset for neurological research, providing precise lesion load measurement.🧠 🔍 Dive into its capabilities: https://bit.ly/48LCr4m

💡 Do you want to learn more about the upcoming European Partnership for Brain Health? On June 30, a session will be dedicated to the Brain Health Partnership at the 10th European Academy of Neurology Congress in Vienna, presenting the work being done in developing an ambitious Strategic Research and Innovation Agenda, outlining the strategic priorities, actions, and initiatives, while encouraging maximum engagement of member states and relevant players in the brain field – including psychiatrists and people living with brain disorders. Learn more: https://lnkd.in/gv_XP5wi

Prof Urs Fischer, Chairman of the Department of Neurology at the University of Basel, has provided an initial insight into the findings of the SWITCH Trial. This pivotal research addresses the significant challenge of treating intracerebral hemorrhage within the field of stroke medicine. "To SWITCH, or not to SWITCH, that is the question." We can't wait to hear more at #ESOC2024. There is still time to register for the conference: https://ow.ly/j2uG50Ryb2u #stroke #strokeresearch #strokescience #strokecare #voiceofstroke

To all neurology aspirant, Try this Quiz.. Our 1st case in ajnr classic case. https://lnkd.in/gnjjgRGn.

On April 15, we’re joining the scientific community at the American Academy of Neurology annual meeting. Catch the oral presentation to learn about initial data from the DELIVER trial of DYNE-251 in people with Duchenne muscular dystrophy amenable to exon 51 skipping. Learn more and register here: https://bit.ly/49jz4ll #AANAM #DMD #clinicaltrials #data #drugdevelopment

The 10th Congress of the European Academy of Neurology will be held in Helsinki from June 29th to July 2nd 🌻 The overarching theme for EAN 2024 is Neuromodulation: advances and opportunities in neurological diseases. EAN Congress will address the current state and future directions of neuromodulation focusing on techniques available as diagnostic tools or therapeutic interventions; how to precisely target specific cortical regions, deep brain structures, and head nerves for therapeutic purposes; and how to advance neuromodulation into new areas of neurology such as chronic minimally conscious state or limb prosthesis. The program is designed to cater to every category of participant from trainees to specialists, for both clinicians and scientists. Days will be filled with knowledge of the latest developments in neurology, Symposia, Workshops, Teaching sessions and inspiring speeches. More info and registration for the EAN Congress 2024 ➡ https://lnkd.in/dnKKvh8m #brainhealthmission #BrainHealth #SuomenNeurologinenYhdistys #FinnishNeurologicalSociety #EuropeanAcademyOfNeurology #Codedtoconnect Neurocenter Finland

Clene Nanomedicine, Inc.'s new #VISIONARYMS data is a medical first! Presented at the American Academy of Neurology Annual Meeting, our results demonstrated significant evidence of axonal repair and remyelination with continuous #CNMAu8 treatment in relapsing-remitting #MS. Read the BioNews Inc.’s #MSNewsToday article to learn more about our #MSresearch: https://bit.ly/3Q773H2

Now presenting at #InnovationSF23: Samantha Scott, PhD of JuneBrain Inc. (Baltimore, MD, USA) who provide accessible monitoring for eye care and neurology. JuneBrain have created the Neuro-i: an AI-driven, wearable eye-scanning device and SaaS platform to detect new disease activity and enable clinicians to track disease progression and patient responses to treatment between clinical visits. Are you staying informed? bit.ly/3QvOw6I

Save on Functional Neurology Management of Concussion Level 1 and Concussion Bootcamp in honor of #braininjuryawarenessmonth! To learn more and save, visit - https://lnkd.in/ewdg8rT8

We've got a fascinating article from the Journal of Neurology, that explores the topic of migraines and the incredible role of Optical Coherence Tomography-Angiography (OCT-A) in migraine research. Migraines are notorious for their cyclic and often debilitating nature. Did you know that up to a third of migraine sufferers experience what's known as an "aura"? Now, here's where OCT-A enters the spotlight! The introduction of OCT-A is a game-changer. This innovative technique enables the non-invasive study of blood flow in the retina and choroid. While previous studies noted changes in retinal vessel densities in migraine patients, OCT-A allows a more in-depth look and helps in documentation of these changes. #MigraineResearch #OCTA #OptovueSolix #Innovation 📖 Read the full article here: https://lnkd.in/eXzV7Unb Also, ask us about year-end offers on OCT-A and maximize savings with your Section 179 tax deduction!